Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Germany / NCT06964724
Active, not recruiting Observational

NeVa Retrospective Comparative SR Study

NCT06964724 · tracked via the Priya Life Science Germany tracker
Sponsor
Vesalio
Phase
Observational
Started
2025-06-15
Last updated
2026-03-31

Condition(s) studied

Stroke Acute

Investigational drug(s) / intervention(s)

Mechanical thrombectomy

Mechanical thrombectomy: Mechanical thrombectomy with stent retriever

Study summary

To compare safety and effectiveness of NeVa Stent Retriever (SR) to Control SR in the treatment of stroke caused by large vessel occlusion. The main questions it aims to answer are:

How do recanalization rates for NeVa SR compare with those of the Control SR? How does NeVa SR safety compare with Control SR safety?

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Treatment during the enrollment period * Age ≥18 * Baseline modified Thrombolysis in Cerebral Infarction (mTICI) score ≤ 1 * Pre-stroke modified Rankin score (mRS) of 0 or 1 * Internal Carotid Artery (ICA), Middle Cerebral Artery (first segment M1/ second segment M2), basilar artery or vertebral artery occlusion * National Institutes of Health Stroke Scale (NIHSS) score ≥ 8 and ≤ 25 * Thrombectomy procedure initiated within 8h of Time Last Known Well (TLKW) * Intravenous Tissue Plasminogen Activator (IV-tPA) failed, given within 3h of TLKW, or ineligibility for thrombolytic drug Exclusion Criteria: * First line contact aspiration alone or non-study device as first-line device

Primary outcome measure(s)

  • Reperfusion Effectiveness — Procedural
    Number of patients with a Modified Thrombolysis in cerebral infarction (mTICI) ≥2B and mTICI≥2C recanalization after 1st pass and at end of procedure

Trial sites (5)

FacilityCityRegionStatus
Hospital Espanol de Mendoza Mendoza Argentina
CHU LIege Liège Belgium
UK Munster Münster Germany
Republican Vilnius University Hospital Vilnius Lithuania
İstanbul Aydrn Üniversitesi Istanbul Turkey (Türkiye)

Other trials for the same condition

Sex diffErences in prehoSpitAl Stroke MEdicine Recruiting
Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE) Starting soon
One-Stop manaGemEnT For A Swift Initiation of Endovascular Therapy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06964724 on ClinicalTrials.gov ↗ ← All trials in Germany